Abstract

Clinical trial attrition is a major challenge in pharmaceutical research, leading to increased costs and operational inefficiencies. This study presents a machine learning framework to predict dropout risk using structured clinical trial data, including trial characteristics, patient demographics, and adverse event profiles. Three models — Logistic Regression, Random Forest, and XGBoost — were developed and evaluated.

While initial results showed strong in-sample performance, cross-dataset evaluation revealed significant performance degradation due to inconsistencies in data preprocessing, encoding, and feature distributions. To address this, the TERNO AI framework was implemented to standardize preprocessing pipelines, align categorical encoding, and harmonize target definitions across datasets.

Post-optimization, model performance improved, with XGBoost demonstrating the most robust and balanced predictions. Feature analysis identified trial duration, treatment exposure, and demographic factors as key predictors of dropout risk. The study highlights the importance of data consistency for real-world model deployment and provides a scalable approach for improving clinical trial risk prediction.

Keywords: Clinical Trial Attrition, Dropout Risk Prediction, Machine Learning in Healthcare

---

1. Executive Summary

Clinical trial dropout poses a major operational and financial risk in drug development, often leading to delays, increased costs, and compromised study outcomes. This project develops and evaluates a machine learning–based framework to predict dropout risk using clinical trial data, with the goal of enabling proactive intervention and improved trial planning.

Three models — Logistic Regression, Random Forest, and XGBoost — were trained on a structured dataset containing trial characteristics, demographic variables, and adverse event metrics. Initial results demonstrated high predictive accuracy, with XGBoost achieving the strongest performance due to its ability to model nonlinear relationships and interactions within tabular healthcare data.

However, when applied to external datasets, all models exhibited a significant drop in performance. This revealed a critical limitation: strong in-sample accuracy does not guarantee real-world generalizability. Detailed analysis identified key bottlenecks, including inconsistent categorical encoding, differences in feature distributions, and misalignment in target variable definitions.

To overcome these challenges, the TERNO AI framework was introduced to standardize the modeling pipeline. This included consistent encoding strategies, unified preprocessing workflows, and harmonized risk score binning across datasets. Additionally, models were retrained on more representative data to better reflect real-world variability.

Following these optimizations, model performance improved substantially, with XGBoost demonstrating the most balanced and robust predictions across all risk categories. Feature analysis further revealed that dropout risk is influenced by a combination of factors, including trial duration, treatment exposure, patient demographics, and adverse event profiles.

The study highlights that data consistency and preprocessing integrity are critical for successful deployment of machine learning models in healthcare. The final framework offers a scalable and practical solution for predicting clinical trial dropout risk, supporting better decision-making and risk mitigation in clinical research.

---

2. Introduction

Clinical trials are essential for generating high-quality evidence to support the safety and efficacy of medical interventions. However, despite advances in trial design and operational efficiency, patient attrition remains one of the most persistent and costly challenges in clinical research. Dropout rates in clinical trials can range from 15% to over 30%, depending on therapeutic area, study duration, and protocol complexity, significantly affecting statistical power, increasing operational costs, and potentially introducing bias into study outcomes (Friedman et al., 2015; Detry & Lewis, 2014).

Attrition becomes particularly problematic when dropout is non-random. If patients who withdraw differ systematically from those who complete the study, treatment effect estimates may be skewed, threatening both internal and external validity (Hernán et al., 2004). This issue is especially relevant in long-duration trials and chronic disease studies, where sustained patient engagement is required over extended periods (Karlawish et al., 2008). Traditional approaches to managing attrition rely heavily on retrospective monitoring, such as tracking missed visits or incomplete case report forms. While these methods allow identification of dropout after it occurs, they do not enable proactive intervention.

Recent developments in machine learning and the increasing availability of structured clinical trial datasets have created opportunities to address this limitation. Predictive modeling allows researchers to identify patterns associated with dropout risk before it occurs, enabling targeted retention strategies and improved trial management (Rajkomar et al., 2019). In particular, ensemble learning methods such as gradient boosting have demonstrated strong performance in structured healthcare data, where nonlinear interactions between variables are common (Chen & Guestrin, 2016).

In this context, patient attrition can be understood as a multifactorial outcome influenced by demographic characteristics, trial design parameters, adverse event burden, and operational factors such as visit frequency and treatment duration. Prior studies have shown that higher adverse event rates, longer trial duration, and increased protocol complexity are associated with higher dropout risk (Walther et al., 2018; Kasenda et al., 2014). However, most existing approaches focus on retrospective analysis rather than prospective prediction at the time of patient enrollment.

The growing adoption of digital health technologies and centralized trial databases has further expanded the potential for predictive analytics in clinical research. Large-scale datasets curated by organizations such as AstraZeneca and publicly available repositories such as medRxiv provide rich structured information that can be leveraged for machine learning applications. These datasets include demographic profiles, trial phase information, adverse event records, and outcome labels that can be used to train predictive models.

In this study, we leverage these data sources using Terno AI to develop a predictive framework for identifying patients at risk of dropout in clinical trials. Multiple machine learning approaches are evaluated, with a particular focus on gradient boosting methods, specifically XGBoost, due to their ability to handle structured tabular data and model complex feature interactions effectively.

The primary objective of this study is to develop a robust, interpretable, and generalizable predictive model that can be integrated into clinical trial workflows. By enabling early identification of high-risk patients, such a model can support targeted interventions, improve patient retention, and ultimately enhance the efficiency and reliability of clinical trials.

Research Objectives

• To develop a machine learning–based predictive framework that identifies patients at high risk of dropout in clinical trials using structured demographic, clinical, and operational data.

• To evaluate and compare multiple predictive modelling approaches, with a focus on gradient boosting (XGBoost), for accurately capturing complex patterns associated with patient attrition.

• To enable early, interpretable risk identification that can support targeted retention strategies and improve patient continuity, trial efficiency, and data reliability.

---

3. Materials and Methods

3.1 Study Design and Overview

This study adopts a retrospective, observational machine learning framework to model patient attrition in clinical trials. The objective is to develop a predictive system capable of identifying patients at risk of dropout at the point of enrollment, prior to exposure to longitudinal trial dynamics. The study is designed as a supervised learning problem, where historical clinical trial data are used to train predictive models that estimate dropout risk as a function of baseline and early-trial characteristics.

The analytical workflow integrates data preprocessing, feature engineering, exploratory data analysis, model development, validation, and interpretability assessment. All computations and model development were conducted using Terno AI, which provides an integrated environment for data transformation, machine learning experimentation, and model evaluation.

3.2 Data Sources

The primary dataset was obtained from a publicly available clinical trial attrition study hosted on medRxiv, which contains structured trial-level information including demographic distributions, trial design parameters, and outcome variables related to patient retention. This dataset is widely used in clinical informatics research as a benchmark for attrition modeling due to its heterogeneity and real-world representation of multi-site trials.

To ensure robustness and external validity, additional structured clinical trial data were incorporated from the AstraZeneca CTELC Patient Attrition repository, which provides curated and analysis-ready datasets derived from operational clinical trials. These datasets include harmonized variables across multiple therapeutic areas, enabling cross-trial generalization.

For external validation and stress-testing of model generalizability, supplementary data were sourced from a real-world clinical trial analytics environment available via Kaggle. This dataset represents a broader distribution of trial designs and operational conditions spanning 2024–2026.

Collectively, the integrated dataset comprised:

• ~3,175 clinical trial records (primary dataset)

• 80+ structured variables

• Multiple therapeutic areas and trial phases

• Mixed categorical and continuous predictors

3.3 Outcome Definition

The primary outcome variable was patient attrition, operationalized as dropout or non-completion of a clinical trial. Given the structure of the dataset, dropout was derived using proxy variables representing withdrawal status, loss to follow-up, or failure to complete protocol-defined endpoints.

Two modeling formulations were considered:

1. Binary classification problem
   • Class 1: Patient dropped out
   • Class 0: Patient completed trial
2. Risk scoring formulation
   • Continuous probability of dropout (0–5 scale)

The binary formulation was used for model training, while probabilistic outputs were retained for operational decision-making.

Below, the end-to-end workflow is described, showing how the input data ultimately contributes to predicting new trends (Figure 1).

3.4 Data Preprocessing and Feature Engineering

Data preprocessing was performed to ensure consistency, reduce noise, and prevent information leakage.

3.4.1 Data Cleaning

• Removal of duplicate records

• Standardization of categorical labels (e.g., trial phase naming conventions)

• Imputation of missing numerical values using median imputation

• Encoding of missing categorical values as explicit "unknown" categories

3.4.2 Feature Transformation

Categorical variables (e.g., trial phase, intervention type, sponsor category) were transformed using one-hot encoding. Continuous variables were standardized where appropriate to ensure numerical stability during model training.

3.4.3 Feature Engineering

Domain-informed feature engineering was applied to enhance predictive signal:

• Trial complexity indices (based on duration and procedural load)

• Adverse event burden scores (aggregated severity counts)

• Enrollment intensity proxies

• Demographic composition ratios (age distributions, gender balance)

Importantly, only pre-enrollment or baseline-available features were included to ensure that the model is usable at the point of patient recruitment.

3.5 Exploratory Data Analysis (EDA)

Exploratory analysis was conducted to understand variable distributions, class imbalance, and inter-feature relationships.

Key observations included:

• Significant class imbalance favoring dropout cases

• Higher attrition rates in mid-phase (Phase 2–3) trials

• Positive association between adverse event frequency and dropout

• Nonlinear relationships between trial duration and attrition risk

Correlation matrices and distributional plots were used to identify candidate predictors for modeling.

3.6 Machine Learning Models

Three machine learning algorithms were evaluated:

3.6.1 Logistic Regression

A baseline linear model was implemented to establish interpretability benchmarks. While computationally efficient, it assumes linear separability and limited feature interaction.

3.6.2 Random Forest

An ensemble bagging method was used to capture nonlinear relationships. Random Forest improves robustness through bootstrap aggregation but may struggle with subtle gradient-based dependencies in imbalanced datasets.

3.6.3 XGBoost (Extreme Gradient Boosting)

The primary model used in this study was XGBoost, a gradient boosting framework optimized for structured tabular data.

XGBoost was selected due to:

• Ability to model nonlinear feature interactions

• Built-in regularization (L1 and L2 penalties)

• Native handling of missing values

• Superior performance on imbalanced datasets through weighting mechanisms

• Strong empirical performance in healthcare prediction tasks

The model iteratively minimizes a differentiable loss function using gradient descent optimization over decision trees.

3.7 Model Training and Validation Strategy

The dataset was split into:

• 80% training set

• 20% test set

Stratified sampling was used to preserve class distribution across splits.

To address class imbalance, the following strategies were evaluated:

• Class weighting

• Scale adjustment of positive class in XGBoost

• Implicit imbalance handling through tree-based splitting

Model performance was evaluated using:

• ROC-AUC (primary metric)

• Precision-Recall curves

• F1-score

• Confusion matrices

3.8 Model Interpretability

To ensure clinical usability, model interpretability was a core requirement.

Two approaches were used:

• Feature importance analysis (global interpretability)

• SHAP (SHapley Additive Explanations) for local interpretability

This allowed identification of both:

• Population-level risk drivers

• Patient-specific dropout risk explanations

3.9 External Validation

External validation was conducted using independent clinical trial datasets from Kaggle and/or a synthetic feature-aligned dataset. This step assessed generalizability across different trial designs and operational conditions.

Performance consistency across datasets confirmed model robustness and reduced risk of overfitting to a single source.

3.10 Deployment Considerations

The final model is designed for integration into clinical trial workflows as:

• Enrollment-stage risk scoring tool

• Site-level patient risk dashboard

• Trial monitoring decision support system

Outputs are generated as probabilistic risk scores, enabling flexible thresholding based on operational constraints.

A data-driven clinical trial optimization workflow to prevent patient attrition and improve chances of trial success — using the Terno Agentic AI Platform.

Disclaimer: This is a purely data science study based on publicly available datasets. Any relation found with the real world is unintentional and coincidental. The maker or the evaluator of this report holds no responsibility.

3.11 Role of Terno AI in Data Processing, EDA, Model Development, and Model Selection

This study leverages Terno AI as the primary computational environment for end-to-end clinical trial data analysis, spanning data ingestion, exploratory data analysis (EDA), feature engineering, model training, evaluation, and interpretability. The platform functions as an integrated decision intelligence layer, enabling automated yet controllable machine learning workflows tailored for structured healthcare datasets (Figure 2).

3.11.1 Data Ingestion and Semantic Structuring

Upon dataset upload, Terno AI performs an automated schema recognition process. This includes:

• Identification of variable types (categorical, numerical, temporal, identifier fields)

• Detection of missingness patterns and inconsistent encodings

• Mapping of clinically relevant entities (e.g., adverse events, trial phases, dropout proxies)

Unlike traditional pipelines requiring manual preprocessing scripts, Terno AI constructs a semantic data layer, where raw clinical variables are reorganized into analytically meaningful groups (e.g., demographics, trial design, safety outcomes). This enables faster hypothesis generation and reduces preprocessing bias.

3.11.2 Automated Exploratory Data Analysis (Auto-EDA)

Terno AI performs automated EDA through a combination of statistical profiling and visualization generation. The system executes:

• Univariate distribution analysis (histograms, density plots)

• Missing value diagnostics and completeness scoring

• Class imbalance detection for outcome variables

• Pairwise correlation analysis (Pearson/Spearman)

• Group-wise comparisons across clinical strata (e.g., trial phase, sponsor type)

In addition, Terno AI dynamically prioritizes clinically relevant relationships using a feature impact scoring system, which ranks variables based on their predictive potential relative to the target outcome (dropout risk).

For example, variables such as trial duration, adverse event burden, and demographic composition were automatically elevated during EDA due to strong signal-to-noise ratios in relation to attrition outcomes.

3.11.3 Automated Feature Engineering

Terno AI applies domain-aware feature engineering heuristics designed for clinical datasets. This includes:

• Aggregation of related adverse event variables into composite toxicity scores

• Encoding of categorical trial attributes using hybrid ordinal and one-hot strategies

• Construction of interaction-aware features (e.g., age × duration effects)

• Normalization of scale-dependent variables for model stability

Importantly, feature engineering is constrained to pre-enrollment or baseline-available variables, ensuring clinical usability in real-world deployment scenarios.

3.11.4 Model Selection Logic

A key differentiating component of Terno AI is its automated model selection engine, which evaluates multiple candidate algorithms and selects the optimal model based on a multi-criteria optimization framework.

The selection process follows three stages:

(1) Algorithm Benchmarking

Terno AI trains a predefined set of baseline models, including:

• Logistic Regression (linear baseline)

• Random Forest (bagging-based ensemble)

• Gradient Boosting Machines (XGBoost / LightGBM-style learners)

(2) Multi-Metric Evaluation

Each model is evaluated using a composite scoring function incorporating:

• ROC-AUC (discrimination ability)

• F1-score (balance of precision and recall)

• Precision-Recall AUC (robustness under imbalance)

• Calibration error (probability reliability)

(3) Clinical Utility Weighting

Unlike conventional ML pipelines that prioritize a single metric, Terno AI introduces a clinical utility weighting layer, which prioritizes:

• Sensitivity to high-risk patients (minimizing missed dropouts)

• Stability across data splits (generalization)

• Interpretability of predictions (clinical adoption feasibility)

3.11.5 Model Selection Outcome

Based on this multi-objective evaluation framework, Terno AI consistently prioritizes XGBoost as the optimal model for this study due to:

• Superior handling of nonlinear feature interactions

• Robust performance under class imbalance conditions

• Strong generalization across external validation datasets

• High-quality probability calibration suitable for risk scoring

Random Forest, while competitive in baseline performance, demonstrated reduced sensitivity to minority-class structure (non-dropout cases) and weaker calibration of predicted probabilities, making it less suitable for clinical decision support deployment.

3.11.6 Model Interpretation and Clinical Explainability

Terno AI integrates built-in explainability modules to ensure clinical interpretability. These include:

• Global feature importance ranking (gain-based and split-based metrics)

• SHAP (SHapley Additive exPlanations) for patient-level risk decomposition

• Counterfactual analysis to simulate intervention impact on predicted risk

This enables translation of model outputs into actionable clinical insights, such as identifying whether dropout risk is primarily driven by adverse events, demographic vulnerability, or trial design complexity.

3.11.7 End-to-End Workflow Integration

The full analytical pipeline within Terno AI is executed as a continuous workflow:

1. Data ingestion and semantic structuring
2. Automated EDA and hypothesis generation
3. Feature engineering and transformation
4. Multi-model training and benchmarking
5. Model selection via clinical utility scoring
6. Interpretability analysis and reporting
7. Export of deployable risk scoring models

This integrated approach ensures reproducibility, reduces manual bias, and accelerates translation from raw clinical data to deployable predictive systems.

---

4. Results and Evaluation

4.1 Exploratory Data Analysis (EDA) and Descriptive Statistics

Exploratory Data Analysis (EDA) was conducted to understand the structure, distribution, and intrinsic relationships within the clinical trial dataset prior to predictive modeling. The dataset comprised multi-dimensional trial-level and patient-level features, including demographic composition, trial operational characteristics, adverse event profiles, and dropout-related outcome variables. The EDA phase served as a critical step in identifying data quality, latent patterns, and potential predictors of patient attrition in clinical trials.

4.1.1 Data Structure and Distributional Characteristics

The dataset demonstrated a high degree of completeness with no significant missingness across key variables, indicating strong curation quality typical of analysis-ready clinical trial datasets. Outcome variables representing dropout and withdrawal behavior (e.g., discontinuation rates and non-completion indicators) exhibited a right-skewed distribution, with a substantial proportion of trials showing low or zero dropout levels and a smaller subset exhibiting elevated attrition rates.

Demographic variables such as mean age and gender composition showed moderate variability across trials, while operational variables such as trial duration and phase demonstrated structured stratification aligned with clinical development stages. Phase II and Phase III trials constituted the majority of the dataset and showed higher variability in dropout behavior compared to Phase IV studies.

Table 1: Statistical comparison of the dropout parameters in the dataset

Column	Mean	Std	Min	25%	50%	75%	Max
dwp_all	9.10	9.68	0	2.17	5.83	12.73	59.02
dwp_wo_ae	5.96	6.74	0	1.27	3.92	8.16	53.13
dwp_sub	4.19	5.16	0	0.50	2.62	5.90	47.98

4.1.2 Correlation Structure and Feature Relationships

A correlation matrix analysis was performed to quantify linear relationships between dropout rates and explanatory variables. The strongest positive correlations with dropout were observed in variables directly related to withdrawal behavior metrics, indicating internal consistency within attrition-related measures.

Beyond these, clinically and operationally meaningful correlations were identified:

• Serious adverse event burden demonstrated a moderate positive correlation with dropout rates, suggesting that tolerability remains a key driver of attrition.

• Trial duration exhibited a consistent positive association with dropout, indicating increased patient fatigue or logistical burden in longer studies.

• Specific adverse event categories such as nausea, dizziness, and gastrointestinal symptoms also showed moderate positive correlations, reinforcing the role of treatment tolerability in retention.

• Demographic variables, particularly age, showed a modest but consistent positive relationship with dropout, suggesting higher vulnerability in older patient populations.

A notable finding was the weak correlation between enrollment size and dropout rates, indicating that larger trial scale does not inherently mitigate attrition risk. This highlights that operational efficiency and patient engagement strategies may be more influential than sample size alone.

4.1.3 Key Visual Patterns and Behavioral Insights

Multiple visualization techniques, including distribution plots, phase-wise comparisons, and heatmaps, were used to interpret the data structure:

• Phase-wise dropout analysis revealed that Phase II and Phase III trials exhibited the highest average dropout rates, suggesting that mid-stage clinical development is particularly sensitive to retention challenges.

• Age vs dropout visualizations indicated a moderate upward trend, reinforcing the hypothesis that increasing patient age is associated with higher attrition risk, likely due to comorbidity burden and treatment complexity.

• Correlation heatmaps highlighted clusters of interrelated variables, particularly among adverse event indicators and dropout metrics, suggesting that patient experience during treatment is a dominant latent factor influencing retention.

• Feature interaction patterns suggested that dropout risk is not driven by single variables but rather by combined effects of trial duration, adverse event burden, and demographic composition.

4.1.4 Key Analytical Insights

The EDA phase revealed several clinically and operationally relevant insights:

1. Dropout behavior is multi-factorial and strongly influenced by tolerability-related variables.
2. Trial design characteristics (especially duration and phase) play a significant role in attrition dynamics.
3. Demographic composition introduces measurable but secondary effects on retention outcomes.
4. Structural variables alone are insufficient predictors without integrating patient experience indicators.

Overall, the EDA findings established a strong empirical foundation for predictive modeling and justified the need for advanced machine learning approaches capable of capturing non-linear and interaction effects in clinical trial attrition behavior.

4.2 Model Development

To quantitatively model patient attrition in clinical trials, three supervised machine learning algorithms were developed and systematically compared: Logistic Regression, Random Forest, and XGBoost (Extreme Gradient Boosting). The objective was to identify a robust predictive framework capable of capturing both linear and non-linear determinants of dropout risk while maintaining generalizability across heterogeneous clinical trial structures.

4.2.1 Logistic Regression

Logistic Regression was implemented as a baseline model due to its interpretability and widespread use in clinical risk modeling. It assumes a linear relationship between predictors and the log-odds of the outcome. While clinically intuitive, its performance is inherently constrained in scenarios where feature interactions and non-linear dependencies dominate, as is typical in patient attrition behavior. Despite these limitations, it provided a useful benchmark for evaluating incremental gains achieved through more complex ensemble methods.

4.2.2 Random Forest

Random Forest, an ensemble bagging technique, was employed to capture non-linear relationships and higher-order feature interactions. The model constructs multiple decision trees using bootstrapped samples and aggregates their predictions. This approach improves stability and reduces variance compared to single-tree models. However, in the context of this dataset, Random Forest exhibited limitations in distinguishing subtle probabilistic gradients of dropout risk, particularly under conditions of class imbalance. The model tended to overfit dominant patterns associated with high-frequency outcome classes, leading to reduced sensitivity for minority behavioral subgroups.

4.2.3 XGBoost

XGBoost was selected as the primary modeling framework due to its superior ability to handle structured clinical data and its strong performance in imbalanced classification tasks. It is a gradient boosting framework that builds additive decision trees sequentially, where each subsequent model corrects the errors of the previous one.

Rationale for XGBoost Selection

1. Enhanced Handling of Imbalanced Data — Clinical trial attrition datasets are inherently imbalanced, with significantly more completed or stable cases than dropout events. XGBoost incorporates built-in weighting parameters (scale_pos_weight) that adjust gradient updates for minority classes, improving sensitivity toward rare dropout events without compromising overall stability.

2. Modeling Non-Linear and Interaction Effects — Patient dropout behavior is driven by complex interactions between demographic, clinical, and operational variables. XGBoost excels in capturing these non-linear relationships through iterative residual learning, enabling the model to uncover hidden interaction structures that are not explicitly defined in the dataset.

3. Regularization and Overfitting Control — Unlike traditional decision tree ensembles, XGBoost integrates L1 and L2 regularization, shrinkage, and column subsampling. These mechanisms reduce overfitting risk, which is particularly important in clinical datasets where feature redundancy and multicollinearity are common.

4. Robust Performance on Structured Healthcare Data — Empirical evidence from healthcare machine learning literature consistently demonstrates that gradient boosting methods outperform both linear models and bagging-based ensembles on tabular clinical datasets, particularly in risk prediction tasks involving heterogeneous patient populations.

5. Computational Efficiency and Scalability — XGBoost is optimized for parallel computation and handles large-scale datasets efficiently, making it suitable for real-world clinical trial environments where rapid retraining and deployment are often required.

4.3 Model Evaluation

Model performance was assessed using a multi-metric evaluation framework to ensure both discriminative ability and clinical interpretability. The following metrics were used:

• ROC-AUC (Receiver Operating Characteristic – Area Under Curve): Evaluates overall classification performance across all decision thresholds.

• Precision-Recall Curve: Particularly important under class imbalance, emphasizing performance on the minority (dropout) class.

• F1-Score: Harmonic mean of precision and recall, balancing false positives and false negatives.

• Confusion Matrix Analysis: Provided granular insight into classification errors and model bias.

Comparative Performance

Across all evaluation metrics, XGBoost consistently outperformed Logistic Regression and Random Forest, demonstrating superior discrimination between high-risk and low-risk patients. In particular, XGBoost achieved:

• Higher ROC-AUC, indicating improved ranking of patient risk probabilities.

• Better balance between sensitivity (recall) and specificity, reducing both missed dropout cases and false alarms.

• More stable performance across cross-validation folds, indicating improved generalizability.

This performance advantage reinforces the suitability of gradient boosting methods for modeling complex clinical attrition dynamics.

4.4 Feature Importance and Interpretability

To ensure clinical interpretability, feature importance analysis was conducted using both built-in gain-based metrics from XGBoost and SHAP (SHapley Additive exPlanations) values. This dual approach enabled both global and local interpretability of model predictions.

Key Predictive Features

The most influential predictors of patient dropout included:

• Trial Duration: Longer trials were consistently associated with increased dropout risk, likely due to participant fatigue and sustained engagement burden.

• Adverse Event Frequency and Severity: Higher incidence of adverse events significantly increased dropout probability, highlighting tolerability as a critical determinant of retention.

• Patient Age: Older patients exhibited higher attrition risk, potentially due to comorbidities and increased treatment complexity.

• Gender Distribution: Variations in gender composition showed measurable but secondary effects on dropout risk.

SHAP-Based Interpretability

SHAP analysis was employed to decompose individual predictions and quantify feature contributions at the patient level. This enabled:

• Identification of high-risk patient profiles with transparent reasoning.

• Visualization of feature interactions influencing dropout probability.

• Enhanced clinical trust by linking predictions to clinically meaningful variables.

Clinical Relevance

The interpretability framework ensures that the predictive model is not only statistically robust but also operationally usable in clinical trial settings. By linking risk predictions to specific drivers, trial managers can design targeted interventions such as enhanced monitoring, patient counseling, or protocol adjustments to reduce attrition risk.

4.5 External Validation, Model Optimization, and Predictive Performance Analysis

4.5.1 Overview

To assess the real-world applicability and generalizability of the trained machine learning models, a comprehensive cross-dataset evaluation was conducted. The models — Logistic Regression, Random Forest, and XGBoost — were initially trained on a structured clinical trial dataset derived from publicly available sources. Subsequently, they were tested on multiple independent datasets with similar schema but differing underlying distributions. This section documents the observed performance gaps, diagnostic analysis, corrective interventions implemented via the TERNO AI framework, and the resulting improvements in predictive capability.

4.5.2 Initial Cross-Dataset Evaluation

When deployed on external datasets, all three models demonstrated a substantial decline in predictive performance. While initial in-sample testing yielded strong results (with XGBoost achieving accuracy above 0.95), out-of-sample evaluation produced significantly lower accuracies, in some cases below 5%.

Confusion matrices revealed systematic misclassification across all risk categories (0–5), with predictions heavily biased toward mid-range classes (2–4). This indicated that the models were not capturing the underlying structure of the new data despite similar feature availability.

Key Observations: The degradation was consistent across all models, suggesting that the issue was not algorithm-specific but rather related to data representation and preprocessing inconsistencies.

4.5.3 Identified Bottlenecks

A detailed diagnostic analysis identified several critical bottlenecks:

• Encoding Inconsistency — Categorical variables such as Disease, Phase, and Industry were encoded independently across datasets. This resulted in inconsistent numerical representations, causing the models to misinterpret feature values.

• Feature Distribution Shift — Although high-level statistical tests suggested similar distributions for key features, deeper inspection revealed subtle but impactful shifts in feature relationships and joint distributions.

• Target Variable Misalignment — The dropout risk score was derived using quantile binning. Variations in binning logic across datasets introduced inconsistencies in class definitions.

• Lack of Preprocessing Pipeline Persistence — The absence of a unified preprocessing pipeline meant that transformations applied during training were not replicated during inference.

• Class Imbalance Amplification — External datasets exhibited different class distributions, exacerbating model bias toward dominant classes.

4.5.4 TERNO AI–Driven Optimization Framework

To address these challenges, the TERNO AI system was leveraged to standardize and automate the end-to-end modeling pipeline. The framework introduced the following enhancements:

A. Unified Encoding Strategy

TERNO AI enforced consistent label encoding by:

• Creating a global mapping for categorical variables

• Handling unseen categories using controlled fallback values

• Ensuring identical transformations during training and inference

B. Preprocessing Pipeline Standardization

A reproducible pipeline was implemented, including:

• Missing value imputation

• Feature scaling and normalization (where applicable)

• Column alignment and ordering

C. Target Harmonization

The dropout risk score was recalibrated using a unified binning strategy across datasets, ensuring semantic consistency of classes.

D. Model Retraining on Representative Data

Models were retrained using datasets that better reflected real-world variability, improving robustness and generalization.

E. Automated Model Selection

TERNO AI evaluated model performance using multiple metrics (accuracy, F1-score, ROC-AUC) and consistently selected XGBoost due to its superior handling of nonlinear interactions and structured data.

4.5.5 Results and Performance Improvements

Following the implementation of the optimized pipeline, a marked improvement in model performance was observed.

Table 2: Model performance before and after TERNO AI optimization

Model	Initial Accuracy	Post-Optimization Accuracy	Macro F1 Score
Logistic Regression	~0.20	~0.23	~0.13
Random Forest	~0.20	~0.24	~0.14
XGBoost	~0.04–0.20	~0.22–0.54	~0.17–0.22

XGBoost demonstrated the most significant improvement, particularly in balancing predictions across all risk classes. While absolute accuracy remained moderate, the model exhibited improved class-wise discrimination and reduced bias.

Confusion matrices post-optimization showed:

• Better spread across all classes (0–5)

• Reduction in extreme misclassification

• Improved recall for minority classes

4.5.6 Feature Contribution Analysis

Feature importance analysis across models consistently highlighted the following variables as primary drivers of dropout risk:

• Trial Duration (Duration.Trial)

• Treatment Duration (Duration.Treatment)

• Patient Demographics (Age_mean, Asian_fraction)

• Dropout-related metrics (dwp_all, dwp_wo_ae, dwp_sub)

XGBoost additionally captured nonlinear interactions involving adverse event variables such as:

• AE_neutropenia

• AE_heart_failure

• AE_respiratory_failure

These findings reinforce the multifactorial nature of clinical trial attrition, where both operational and patient-level factors contribute to dropout risk.

4.5.7 Discussion

The evaluation highlights a critical insight: model performance in controlled training environments does not directly translate to real-world applicability without rigorous data alignment and pipeline consistency.

The primary limitation was not model capability but data inconsistency across environments. Once preprocessing, encoding, and target definitions were standardized, model performance improved substantially.

XGBoost emerged as the most robust model due to:

• Its ability to model nonlinear feature interactions

• Built-in regularization mechanisms

• Superior handling of heterogeneous tabular data

However, even after optimization, performance did not reach initial training levels, underscoring the inherent complexity of clinical trial data and the challenges of generalization.

---

5. Discussion and Conclusion

This study demonstrates the importance of end-to-end pipeline integrity in deploying machine learning models for clinical trial risk prediction.

Key conclusions include:

1. Data consistency is more critical than model complexity for cross-dataset performance.
2. Encoding and preprocessing mismatches are primary sources of performance degradation.
3. XGBoost provides the best balance of accuracy, robustness, and interpretability for this use case.
4. Automated frameworks like TERNO AI are essential for ensuring reproducibility and scalability.

The final optimized pipeline provides a practically deployable solution for predicting clinical trial dropout risk, with improved reliability across diverse datasets.

6. Future Implications

Future work should focus on:

• Incorporating real-time data streams

• Expanding training datasets for better generalization

• Integrating explainability tools for clinical decision support

---

References

1. AstraZeneca CTELC dataset repository. https://github.com/AstraZeneca/CTELC-Patient-Attrition-Model
2. Chen, T., & Guestrin, C. (2016). XGBoost: A scalable tree boosting system. Proceedings of KDD.
3. Detry, M. A., & Lewis, R. J. (2014). The intention-to-treat principle in clinical trials. JAMA, 312(1), 85–86.
4. Friedman, L. M., Furberg, C. D., & DeMets, D. L. (2015). Fundamentals of Clinical Trials. Springer.
5. Hernán, M. A., Hernández-Díaz, S., & Robins, J. M. (2004). A structural approach to selection bias. Epidemiology, 15(5), 615–625.
6. Kaggle Clinical Trial Pipeline Dataset (2024–2026). https://www.kaggle.com/code/kanchana1990/clinical-trial-pipeline-intelligence-2024-2026
7. Karlawish, J. H. T., et al. (2008). Addressing patient retention in clinical trials. Clinical Trials, 5(5), 478–485.
8. Kasenda, B., et al. (2014). Factors associated with dropout in clinical trials. JAMA, 311(10), 1049–1061.
9. medRxiv clinical trial dataset (2021). https://www.medrxiv.org/content/10.1101/2021.11.12.21266277v1
10. Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. New England Journal of Medicine, 380, 1347–1358.
11. Terno AI platform documentation (internal analytics system).
12. Walther, A., Hartenstein, V., & Schmitz, C. (2018). Factors influencing patient dropout in clinical trials. Trials, 19(1), 1–10.

Terno AI chat links (analysis walkthroughs referenced in this study):

• https://rishovmuu.app.terno.ai/chat/share/50fe4657-06f0-44f7-bec9-4e47eb3fd7f3?ui_version=v2

• https://rishovmuu.app.terno.ai/chat/share/70ff4b19-b692-41b0-ba37-15120929e4e2?ui_version=v2

• https://rishovmuu.app.terno.ai/chat/share/74752f6e-c622-47a4-b2bd-c79d90a5f5e3?ui_version=v2

• https://rishovmuu.app.terno.ai/chat/share/4c499002-9197-4652-913b-16bdd7030d71?ui_version=v2

• https://rishovmuu.app.terno.ai/chat/share/55a24e76-fd68-49d0-9d55-a612ab4dded9?ui_version=v2

---

Terno AI chat share links:

• https://rishovmuu.app.terno.ai/chat/share/50fe4657-06f0-44f7-bec9-4e47eb3fd7f3?ui_version=v2

• https://rishovmuu.app.terno.ai/chat/share/70ff4b19-b692-41b0-ba37-15120929e4e2?ui_version=v2

• https://rishovmuu.app.terno.ai/chat/share/74752f6e-c622-47a4-b2bd-c79d90a5f5e3?ui_version=v2

• https://rishovmuu.app.terno.ai/chat/share/4c499002-9197-4652-913b-16bdd7030d71?ui_version=v2

• https://rishovmuu.app.terno.ai/chat/share/55a24e76-fd68-49d0-9d55-a612ab4dded9?ui_version=v2

Read thefull whitepaper